

1 Azosemide Tablets

2 アゾセミド錠

3

4 Azosemide Tablets contain not less than 95.0% and not
5 more than 105.0% of the labeled amount of azosemide
6 ($C_{12}H_{11}ClN_6O_2S_2$: 370.84).

7 **Method of preparation** Prepare as directed under Tablets, with
8 Azosemide.

9 **Identification** To a quantity of powdered Azosemide Tablets,
10 equivalent to 60 mg of Azosemide, add dilute sodium hydroxide
11 TS to make 100 mL, shake, and filter. To 1 mL of the filtrate add
12 dilute sodium hydroxide TS to make 100 mL. Determine the ab-
13 sorption spectrum of this solution as directed under Ultraviolet-
14 visible Spectrophotometry <2.24>: it exhibits maxima between
15 234 nm and 238 nm, between 272 nm and 276 nm and between
16 324 nm and 330 nm.

17 **Purity** Primary aromatic amines —To a quantity of powdered
18 Azosemide Tablets, equivalent to 20 mg of Azosemide, add 5 mL
19 of *N,N*-dimethylformamide, and allow to stand with occasional
20 shaking. Add 12 mL of water, 1.0 mL of a solution of sodium ni-
21 trite (1 in 200) and 2.0 mL of diluted hydrochloric acid (1 in 10)
22 under ice-cooling, shake, and allow to stand for 3 minutes. Add
23 1.0 mL of ammonium amidosulfate TS, shake thoroughly, allow
24 to stand for 3 minutes. Add 1.0 mL of a solution of *N*-1-naph-
25 thylethylenediamine dihydrochloride (1 in 200), shake. Add *N,N*-
26 dimethylformamide to make exactly 50 mL, centrifuge, and use
27 the supernatant as the sample solution. Determine the absorbance
28 of the sample solution at 540 nm as directed under Ultraviolet-
29 visible Spectrophotometry <2.24>, using a solution prepared in the
30 same manner with 5 mL of *N,N*-dimethylformamide under ice-
31 cooling, as the blank: the absorbance is not more than 0.15.

32 **Uniformity of dosage unit** <6.02> Perform the Mass variation
33 test, or the Content uniformity test according to the following
34 method: it meets the requirement.

35 To 1 tablet of Azosemide Tablets add dilute sodium hydroxide
36 TS to make exactly V mL so that each mL contains about 0.6 mg
37 of azosemide ($C_{12}H_{11}ClN_6O_2S_2$), shake thoroughly, and centrifuge.
38 Pipet 10 mL of the supernatant liquid, add dilute sodium hydrox-
39 ide TS to make exactly 100 mL. Pipet 10 mL of this solution, add
40 dilute sodium hydroxide TS to make exactly 50 mL, and use this
41 solution as the sample solution. Separately, weigh accurately
42 about 60 mg of azosemide for assay, previously dried at 105°C for
43 3 hours, and dissolve in dilute sodium hydroxide TS to make ex-
44 exactly 100 mL. Pipet 10 mL of this solution, and add dilute sodium
45 hydroxide TS to make exactly 100 mL. Pipet 10 mL of this solu-
46 tion, add dilute sodium hydroxide TS to make exactly 50 mL, and
47 use this solution as the standard solution. Determine the absorb-
48 ances, A_T and A_S , at 274 nm of the sample solution and standard
49 solution as directed under Ultraviolet-visible Spectrophotometry
50 <2.24>.

51 Amount (mg) of azosemide ($C_{12}H_{11}ClN_6O_2S_2$)

$$52 = M_S \times A_T / A_S \times V / 100$$

53 M_S : Amount (mg) of azosemide for assay taken

54 **Dissolution** <6.10> When the test is performed at 50 revolutions
55 per minute according to the Paddle method, using 900 mL of 2nd
56 fluid for dissolution test as the dissolution medium, the dissolution
57 rate in 60 minutes of 30-mg tablet and in 90 minutes of 60-mg
58 tablet are not less than 70%, respectively.

59 Start the test with 1 tablet of Azosemide Tablets, withdraw not
60 less than 20 mL of the medium at the specified minute after start-
61 ing the test, and filter through a membrane filter with a pore size
62 not exceeding 0.5 μm . Discard the first 10 mL of the filtrate, pipet
63 V mL of the subsequent filtrate, and add the dissolution medium
64 to make exactly V' mL so that each mL contains about 33 μg of
65 azosemide ($C_{12}H_{11}ClN_6O_2S_2$). Pipet 8 mL of this solution, add 0.2
66 mol/L sodium hydroxide TS to make exactly 20 mL, and use this
67 solution as the sample solution. Separately, weigh accurately
68 about 22 mg of azosemide for assay, previously dried at 105°C for
69 3 hours, and dissolve in 0.2 mol/L sodium hydroxide TS to make
70 exactly 100 mL. Pipet 5 mL of this solution, add 0.2 mol/L sodium
71 hydroxide TS to make exactly 50 mL. Pipet 15 mL of this solution,
72 add the dissolution medium to make exactly 25 mL, and use this
73 solution as the standard solution. Determine the absorbances, A_T
74 and A_S , at 274 nm of the sample solution and standard solution as
75 directed under Ultraviolet-visible Spectrophotometry <2.24>.

76 Dissolution rate (%) with respect to the labeled amount of azo-
77 semide ($C_{12}H_{11}ClN_6O_2S_2$)

$$78 = M_S \times A_T / A_S \times V' / V \times 1 / C \times 135$$

79 M_S : Amount (mg) of azosemide for assay taken

80 C : Labeled amount (mg) of azosemide ($C_{12}H_{11}ClN_6O_2S_2$) in 1
81 tablet

82 **Assay** Weigh accurately the mass of not less than 20 tablets of
83 Azosemide Tablets, and powder. Weigh accurately a portion of the
84 powder, equivalent to about 60 mg of azosemide
85 ($C_{12}H_{11}ClN_6O_2S_2$), add dilute sodium hydroxide TS to make ex-
86 exactly 100 mL, shake thoroughly, and filter. Discard the first 5 mL
87 of the filtrate, pipet 5 mL of the subsequent filtrate, add exactly 10
88 mL of the internal standard solution, add the mobile phase to make
89 100 mL, and use this solution as the sample solution. Separately,
90 weigh accurately about 60 mg of azosemide for assay, previously
91 dried at 105°C for 3 hours, dissolve in dilute sodium hydroxide
92 TS to make exactly 100 mL. Pipet 5 mL of this solution, add ex-
93 exactly 10 mL of the internal standard solution, add the mobile phase
94 to make 100 mL, and use this solution as the standard solution.
95 Perform the test with 10 μL each of the sample solution and stand-
96 ard solution as directed under Liquid Chromatography <2.01> ac-
97 cording to the following conditions, and calculate the ratios, Q_T
98 and Q_S of the peak area of azosemide to that of the internal stand-
99 ard.

100 Amount (mg) of azosemide ($C_{12}H_{11}ClN_6O_2S_2$)

101
$$= M_s \times Q_r / Q_s$$

102 M_s : Amount (mg) of azosemide for assay taken

103 *Internal standard solution* — A solution of propyl parahy-
104 droxybenzoate in the mobile phase (3 in 5000).

105 *Operating conditions* —

106 Detector: An ultraviolet absorption photometer (wavelength:
107 280 nm).

108 Column: A stainless steel column 4.6 mm in inside diameter and
109 15 cm in length, packed with octadecylsilanized silica gel for
110 liquid chromatography (5 μ m in particle diameter).

111 Column temperature: A constant temperature of about 25°C.

112 Mobile phase: A mixture of 0.03 mol/L potassium dihydrogen
113 phosphate, acetonitrile and methanol (55:27:18)

114 Flow rate: Adjust so that the retention time of azosemide is
115 about 5 minutes.

116 *System suitability* —

117 System performance: When the procedure is run with 10 μ L of
118 the standard solution under the above operating conditions,
119 azosemide and the internal standard are eluted in this order with
120 the resolution between these peaks being not less than 8.

121 System repeatability: When the test is repeated 6 times with 10
122 μ L of the standard solution under the above operating conditions,
123 the relative standard deviation of the ratio of the peak area of
124 azosemide to that of the internal standard is not more than 1.0%.

125 **Containers and storage** Containers — Tight containers.

126 **Add the following to 9.41 Reagents, Test**

127 **Solutions:**

128 **Azosemide for assay** $C_{12}H_{11}ClN_6O_2S_2$ [Same as the mono-
129 graph Azosemide]

130